Preliminary Results of a Retrospective Study on a Regimen Based on Orelabrutinib Combined with Anti-CD20 Monoclonal Antibody in Patients with Marginal Zone Lymphoma

被引：0
|
作者：
Peng, Hongling [1 ]
Xiang, Xixi [2 ]
Rao, Jun [2 ]
Yan, Wenzhe [1 ]
Cui, Yajuan [1 ]
Li, Ji [1 ]
Jiang, Yafeng [1 ]
Zhang, Xi [1 ,2 ]
机构：
[1] Cent South Univ, Xiangya Hosp 2, Dept Hematol, Changsha, Peoples R China
[2] Army Med Univ, Xinqiao Hosp, Med Ctr Hematol, State Key Lab Trauma & Chem Poisoning,Chongqing K, Chongqing, Peoples R China
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-203787
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6293 / 6293
页数：1
相关论文
共 50 条
  • [31] A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL
    Mato, Anthony R.
    Roeker, Lindsey E.
    Eyre, Toby A.
    Nabhan, Chadi
    Lamanna, Nicole
    Hill, Brian T.
    Brander, Danielle M.
    Barr, Paul M.
    Lansigan, Frederick
    Cheson, Bruce D.
    Singavi, Arun K.
    Yazdy, Maryam Sarraf
    Shah, Nirav N.
    Allan, John N.
    Bhavsar, Erica B.
    Rhodes, Joanna
    Kennard, Kaitlin
    Schuster, Stephen J.
    Williams, AnnaLynn M.
    Skarbnik, Alan P.
    Goy, Andre H.
    Goodfriend, Julie M.
    Dorsey, Colleen
    Coombs, Catherine C.
    Tuncer, Hande
    Ujjani, Chaitra S.
    Jacobs, Ryan
    Winter, Allison M.
    Pagel, John M.
    Bailey, Neil
    Schuh, Anna
    Shadman, Mazyar
    Sitlinger, Andrea
    Weissbrot, Hanna
    Muralikrishnan, Sivraj
    Zelenetz, Andrew
    Kirkwood, Amy A.
    Fox, Christopher P.
    BLOOD ADVANCES, 2019, 3 (10) : 1568 - 1573
  • [32] Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma:: a phase II study
    Jäeger, G
    Neumeister, P
    Brezinschek, R
    Höfler, G
    Quehenberger, F
    Linkesch, W
    Sill, H
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2002, 69 (01) : 21 - 26
  • [33] Mechanisms of anti-lymphoma effects of a new humanized anti-CD20 monoclonal antibody, IMMU-106.
    Stein, R
    Hayes, M
    Qu, ZX
    Chen, S
    Rosario, A
    Horak, ID
    Hansen, HJ
    Goldenberg, DM
    BLOOD, 2003, 102 (11) : 298B - 298B
  • [34] CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy
    Massengale, WT
    McBurney, E
    Gurtler, J
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 46 (03) : 441 - 443
  • [35] Preliminary results of a phase I/II study of the humanized anti-CD20 antibody IMMU-106 (hA20) in patients with relapsed non-Hodgkin lymphoma
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (05): : 339 - 341
  • [36] Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma
    Kohl, LP
    Lim, LC
    Thng, CH
    MEDICAL ONCOLOGY, 2000, 17 (03) : 225 - 228
  • [37] Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma
    L-P Koh
    L-C Lim
    C-H Thng
    Medical Oncology, 2000, 17 : 225 - 228
  • [38] The Type II Glycoengineered Humanized Anti-CD20 Monoclonal Antibody MIL62 Combined with Orelabrutinib in Chinese Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Updated Results of a Multicenter, Phase I/IIa Trial
    Shi, Yuankai
    Qin, Yan
    Zang, Aimin
    Li, Yufu
    Yang, Yanli
    Hui Liu
    Gao, Sujun
    Wang, Xinghe
    Zhang, Weijing
    Jin, Zhengming
    Hui Zhou
    Wang Hua-Qing
    Min Wei
    BLOOD, 2022, 140 : 9482 - 9483
  • [39] A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial
    Alexander Grunenberg
    Lisa M. Kaiser
    Stephanie Woelfle
    Birgit Schmelzle
    Andreas Viardot
    Peter Möller
    Thomas F. E. Barth
    Rainer Muche
    Jens Dreyhaupt
    Markus Raderer
    Barbara Kiesewetter
    Christian Buske
    BMC Cancer, 21
  • [40] Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects
    Goldenberg, David M.
    Morschhauser, Franck
    Wegener, William A.
    LEUKEMIA & LYMPHOMA, 2010, 51 (05) : 747 - 755
12345